Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 11/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11778118 | 0.73 | TDP1 (0.54) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL17155339 | 0.73 | AAK1 (0.44) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL17155025 | 0.72 | STK17B (0.55) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL31080085 | 0.72 | STK17B (0.55) | BRD4CA12CA1CA2CA9 | |
| SCHEMBL28350988 | 0.71 | BCHE (0.47) | CACNA1HCACNA1BCACNA1CBRD4PDE3B | |
| SCHEMBL3451508 | 0.69 | RXRA (0.47) | CACNA1HCACNA1BCACNA1CCYP1A2CA12 | |
| SCHEMBL30987278 | 0.69 | CA12 (0.41) | P2RY14BRD4CA12CA1CA2 | |
| SCHEMBL31336469 | 0.68 | MAPT (0.44) | CYP1A2BRD4PDE3BPDE3ATDP1 | |
| SCHEMBL27224473 | 0.68 | PDK2 (0.38) | P2RY14CA12CA1CA2CA9 | |
| SCHEMBL24176682 | 0.67 | PTPN11 (0.46) | CACNA1HCACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107277-A1 | SUBSTITUTED PYRIDAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4129986-A1 | SUBSTITUTED PYRIDAZINE COMPOUND | Astellas Pharma Inc. (JP) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107277-A1 | SUBSTITUTED PYRIDAZINE COMPOUND | NLRP3, NLRP1, PYCARD | CACNA1H 3629/4885CACNA1B 2290/4885CACNA1C 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.